TP53 and neoplasm: The authors demonstrated that ERK5 deactivation coupled with doxorubicin treatment synergistically enhanced MDM2 nucleolar sequestration and, consequently, promoted PML-mediated p53 upregulation, leading to HeLa and A549 tumor cell apoptosis in vitro and tumor regression in vivo.